Resumen

MOTSE, K G  y  MASHABANE, M J. Sirolimus-induced lymphoedema. SAMJ, S. Afr. med. j. [online]. 2016, vol.106, n.9, pp.886-887. ISSN 2078-5135.  http://dx.doi.org/10.7196/samj.2016.v106i9.11061.

Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant for solid-organ transplant recipients and patients with autoimmune disorders. We report a case of lymphoedema, a rare complication of sirolimus, and discuss the mechanism of drug action, the adverse effects and the challenges of treating a kidney transplant recipient with this complication in a resource-limited environment. Lymphoedema is a rare complication of sirolimus, and the mechanisms are not completely understood; however, early recognition can prevent permanent disfiguration. This case highlights the need for early recognition of adverse drug effects and further research into their pathophysiology and management.

        · texto en Inglés     · Inglés ( pdf )